ArticleBreast (Edinburgh, Scotland)2026
Clinical effect of bisphosphonate in patients with hormone receptor-positive early breast cancer: A nationwide real-world data analysis.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant bisphosphonates (BPs) improve survival in early breast cancer (EBC), particularly among postmenopausal women. However, in Korea, BPs are primarily reimbursed for osteoporosis, limiting their application as adjuvant cancer therapy. This nationwide real-world study aimed to evaluate the impact of BP use on survival and fracture outcomes in Korean women with hormone receptor-positive (HR+) EBC.
methodsWe identified 52,599 women diagnosed with HR + EBC between 2012 and 2019 from the Korea Central Cancer Registry, who underwent surgery and initiated endocrine therapy. BP users (n = 4800) were defined as those prescribed BPs for ≥1-year post-diagnosis. Outcomes included overall survival (OS), recurrence-free survival (RFS), fracture incidence, and fracture-free survival (FFS). Multivariate Cox models incorporating age stratifications and landmark analyses were further applied.
findingsBP use was significantly associated with improved OS. Although the overall RFS was not significant, patients aged ≥60 years showed significant improvements in both OS and RFS. Longer BP exposure (≥3 years) demonstrated consistent OS benefits across the 1-, 2-, and 3-year landmark analyses. Although fractures were higher in BP users, reflecting confounding by indication, age-stratified FFS suggested a potential protective effect against fractures in older patients (≥73 years).
interpretationBP therapy was associated with improved OS and age-dependent (≥60 years) benefits in HR + EBC. Despite higher fracture rates in BP users, age-stratified analyses suggest a fracture-preventive signal in older patients. These findings support adjuvant BP use in selected postmenopausal/high-risk subgroups. Prospective studies are needed to optimize BP timing and duration in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.